Advertisement

Theophylline

  • Elliot F. Ellis
Chapter
  • 114 Downloads
Part of the Current Clinical Practice book series (CCP)

Abstract

Theophylline was introduced into clinical medicine almost 50 yr ago for the treatment of asthma. The drug was widely used for 20 yr after its introduction; however, following reports of adverse reactions, including death, there was a pronounced decline of theophylline prescribing, particularly for children. In the mid 1960s and the early 1970s when the pharmacokinetics of the drug began to be elucidated, an increase in the use of theophylline occurred, and it became the most commonly prescribed drug for the treatment of asthma. During the past decade, because of the introduction and widespread use of new potent anti-inflammatory inhaled steroids, doubts about theophylline’s bronchodilatory activity in acute asthma and renewed concern about theophylline toxicity (well characterized in the 1950s and 1960s), prescription of theophylline substantially decreased. Very recently, however, evidence, first based on in vitro and subsequently on clinical studies, has strongly suggested an immunomodulatory role for theophylline even at low (5–10 µg/mL) serum concentrations.

Keywords

Status Asthmaticus Bronchodilator Effect Serum Theophylline Theophylline Clearance Nocturnal Asthma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Barnes, PJ, Pauwels RA. Theophylline in the Management of Asthma: Time For Reappraisal? Eur Respir J 1994; 7: 579–591.PubMedCrossRefGoogle Scholar
  2. Blake K. Theophylline. In Murphy S, Kelly HW, eds. Pediatric Asthma, Lung Biology in Health and Disease. New York, Dekker, 1999, vol 126.Google Scholar
  3. Ellis ER Theophylline toxicity. JAllergy Clin Immunol 1985; 76: 297–301.CrossRefGoogle Scholar
  4. Hendeles L, Weinberger M, Szefler S, et al. Safety and efficacy of theophylline in children with asthma. J Pediatr 1992; 151: 1907–1914.Google Scholar
  5. Kidney J, Dominguez M, Taylor P, et al. Immunomodulation by theophylline in asthma. Am J Respir Crit Care Med 1995; 151: 1907–1914.PubMedCrossRefGoogle Scholar
  6. May CD. History of the introduction of theophylline into the treatment of asthma Clin Allergy 1974; 4: 211–217.PubMedCrossRefGoogle Scholar
  7. Proceedings of the Theophylline Forum, Stockholm. Clin Exp Allergy 1996; 26 (suppl 2): 1–59.Google Scholar
  8. Selby C, Engleman H, Fitzpatrick M, et al. Inhaled salmeterol or oral theophylline in nocturnal asthma ? Am J Respir Crit Care Med 1997; 155: 104–108.PubMedCrossRefGoogle Scholar
  9. Vassallo R, Lipsky JJ. Theophylline: Recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998; 73: 346–354.PubMedCrossRefGoogle Scholar
  10. Weinberger M, Hendeles L. Theophylline. In: Middleton E Jr, Reed CE, Ellis EF, et al, eds. Allergy: Principles and Practice. St. Louis, Mosby, 1998.Google Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Elliot F. Ellis

There are no affiliations available

Personalised recommendations